To read the full story, subscribe or sign in.

Hua Medicine tests glucokinase activator in Chinese diabetics

March 26, 2014

SHANGHAI – Hua Medicine Ltd. has commenced a phase Ib trial for HMS5552, a glucokinase activator (GKA), in early stage type 2 diabetes patients in a multicenter, multidose study in China.

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...